Background: Evidence suggests that the concordance between amyloid-PET and cerebrospinal fluid (CSF) amyloid-␤ (A␤) increases when the CSF A␤ 1-42 /A␤ 1-40 ratio is used as compared to CSF A␤ 1-42 levels alone. Objective: In order to test this hypothesis, we set up a prospective longitudinal study comparing the concordance between different amyloid biomarkers for Alzheimer's disease (AD) in a clinical setting. Methods: Seventy-eight subjects (AD dementia (n = 17), mild cognitive impairment (MCI, n = 48), and cognitively healthy controls (n = 13)) underwent a 
INTRODUCTION
One of the core neuropathological hallmarks of Alzheimer's disease (AD) is the parenchymal plaques composed of amyloid-␤ (A␤), produced through the sequential proteolytic cleavage of the amyloid-␤ protein precursor by ␤-and ␥-secretases [1, 2] . A␤ is thought to initiate and propagate disease pathology, including deposition of A␤ into neuritic plaques, neurofibrillary tangle formation, neuronal cell loss, and synaptic degeneration, which begins decades before symptom onset [3, 4] .
The process of A␤ proteolytic cleavage generates the release of several A␤ isoforms [5] , amongst which A␤ of 42 amino acids (A␤ ) has the highest propensity to aggregate into amyloid plaques. To date, cerebrospinal fluid (CSF) A␤ , together with total tau protein (T-tau) and tau phosphorylated at threonine 181 (P-tau 181 ), are integrated in the revised research criteria of AD [6] [7] [8] [9] [10] . Concentrations of CSF A␤ are decreased in AD, whereas tau values increase in concentration. The inverse correlation between CSF A␤ and amyloid plaques is believed to be due to accumulation of A␤ into plaques [11] . Besides detecting A␤ in CSF, the amyloid burden may be directly visualized using amyloid positron emission tomography (PET) imaging. Visual assessment of amyloid-PET correlates closely with A␤ deposition at autopsy [12] . Total volume of distribution (V T ) estimated from dynamic imaging with arterial blood sampling is the gold standard for quantification of fibrillar A␤ load [13] . However, due to practical considerations including invasive longitudinal scanning and an extensive pharmacokinetic modeling procedure, most studies have used a simplified quantification method, the standardized uptake value ratio (SUVR). This semi-quantitative measure is calculated as the ratio of radioactivity concentration in the target and reference regions, and is derived from a static scan. The entire cerebellum and cerebellar grey matter are widely used as reference regions as they are devoid of amyloid plaques in sporadic AD [14, 15] .
Although both A␤ markers detect the same neuropathological characteristic, a proportion of subjects within the AD spectrum show discordance between CSF A␤ and amyloid-PET status, with either abnormal CSF A␤ and normal amyloid-PET or vice versa [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . As hypothesized by several groups, the abnormal amyloid metabolism in AD can be detected by CSF biomarkers at a very early stage, before PET imaging becomes abnormal [32] , which should be in line with more individuals with discordant positive CSF (CSF+/PET-) compared to isolated discordant negative CSF (CSF-/PET+) [16, 18, 25, 31] . However, CSF-/PET+ has also been reported in both MCI and AD patients [17, 20, 23, 24, 27, 33] . To increase concordance between amyloid markers, it has been suggested to apply shorter isoforms of A␤ (A␤ and A␤ ) in order to calculate A␤ /A␤ and A␤ /A␤ ratios [25, 30, 31] . These ratios may indeed correct for inter-individual variability in the overall A␤ production, since A␤ and A␤ are expected to increase due to higher overall A␤ production, but not decrease (in contrast to A␤ ) as a result of AD pathology [34] [35] [36] . Therefore, we set up a clinical study with a 'combined assessment of amyloid-PET and CSF biomarkers as early diagnostic tools for AD' (COMBAD) to investigate, as a primary aim, whether the concordance between amyloid-PET and CSF amyloid markers improves when the CSF A␤ 1-42 /A␤ ratio is used instead of CSF A␤ alone. A secondary aim consists of the quantitation of amyloid burden by comparing different reference regions (cerebellar grey matter and whole subcortical white matter). For both aims, the concordance between CSF and all available amyloid-PET measurements, namely visual, SUVR, and V T , were investigated.
MATERIALS AND METHODS

Study design
The COMBAD study consists of one baseline and two follow-up investigations for all subjects. As follow-up of subjects included is still ongoing, baseline results are reported only. All examinations were/will be repeated in patients after one and two years. Controls were/will be followed-up annually for two years including the extensive neuropsychological test battery and a brain MRI scan.
In addition, patients were/will be clinically followed-up by the neurologist every six months.
This study was approved by the ethics committees of UAntwerp/Antwerp University Hospital (UZA) and Hospital Network Antwerp (ZNA), Antwerp, Belgium. The COMBAD study combines the assessment of amyloid-PET and CSF biomarkers as early diagnostic tools for AD with as main goal to improve diagnostic accuracy of early A␤ detection. In this, the quantification of SUVR [ 18 F]AV45 measures is questioned as static SUVR could be incorrect when a scan is acquired in a non-equilibrium state [38] and differences in tracer delivery exist between the target region and the reference region in AD [39] . Our hypothesis is that vascular disturbances by (amongst others) amyloidosis, leading to regional heterogeneous flow/perfusion by amyloidosis are underestimated and accounts for variability in SUVR.
Study population
For this ongoing prospective longitudinal study, subjects with clinical suspicion of AD (both MCI and AD dementia) were recruited through the Memory Clinic of ZNA Middelheim and Hoge Beuken. Cognitively healthy elderly consisted of volunteers, mainly spouses of patients who visited the memory clinic.
Clinical diagnostic criteria
All subjects with cognitive decline as well as cognitively healthy controls were diagnosed by a panel of three MDs with expertise in neurodegenerative brain diseases and dementia (SE, SVM, TVDB). In order to keep the panel blinded for clinical diagnoses that were mentioned in the clinical files of the included subjects, the panel based their consensus diagnoses on standardized presentations (by EN) of the information gathered during the baseline clinical diagnostic work-up at enrollment in the study and was not biomarker-based.
The panel made a consensus clinical diagnosis of dementia due to AD by applying NIA-AA criteria [7, 10] . A consensus diagnosis of MCI due to AD was made by the panel based on the NIA-AA criteria [6, [8] [9] [10] , i.e., (1) cognitive complaint, preferably corroborated by an informant; (2) objective cognitive impairment, quantified as performance of more than 1.5 SD below the appropriate mean on the neuropsychological subtests; (3) largely normal general cognitive functioning; (4) essentially intact activities of daily living (basic and instrumental activities of daily living were determined by a clinical interview with the patient and an informant); and (5) not demented.
The inclusion criteria for cognitively healthy elderly were: (1) no neurological or psychiatric antecedents; (2) no organic disease involving the central nervous system following extensive clinical examination; and (3) no cognitive complaint or decline.
Based on the consensus clinical diagnoses, subjects were divided into three groups, namely cognitively healthy controls, MCI, and AD dementia patients.
Neuropsychological examination
The test battery included the confusion assessment method (CAM; delirium is considered by CAM if acute onset or fluctuating course is present in combination with either inattention or disorganized thinking and altered level of consciousness) [40] ; Montreal cognitive assessment (score below 26/30 is indicative for cognitive decline) [41] ; cognitive part of the Cambridge Examination for mental disorders of the elderly [42] (namely the CAMCOG (lower scores are indicative for more severe cognitive dysfunction)), Mini-Mental State Examination (MMSE; higher score corresponds to better cognitive performance) [43] ; Frontal Assessment Battery (lower scores are indicative of more executive problems), visual association test [44] ; Dutch-language version of the national reading test (scores range from 0 to 50 and translated into IQ estimations, higher score for higher IQ estimations) [45] ; repeatable battery for the assessment of neuropsychological status (generates index scores for five neurocognitive domains as well as a total scale index score) [46] ; Geriatric Depression Scale (score from 0-10 indicates no depression, 11-20 indicates a mild depression and 21-30 indicates a severe depression) [47] ; and Apathy Evaluation Scale (score of 38 or higher is indicative for an apathy syndrome) [48] .
In addition, caregivers or relatives of the subjects were asked to describe the patient's history based on a demographic interview (including demographic information, medical history, medication use (cholinesterase inhibitors), and family history of dementia), and to fill out the Clinical Dementia Rating (higher score indicates more severe dementia symptoms) [49] part for the caregiver, instrumental activities of daily living (lower scores indicate more problems with daily life activity) questionnaire, and the neuropsychiatric inventory [50] .
CSF sampling and storage
CSF samples were collected at ZNA Middelheim and Hoge Beuken according to standard collection protocols as described previously [51] . CSF was obtained by LP at the L3/L4 or L4/L5 interspace and the fluid was collected in polypropylene vials (Nalgene ® cat.no.5000-1020, 1.5 mL). CSF samples were immediately frozen in liquid nitrogen and stored at -75 • C until analysis.
CSF analyses and interpretation of CSF biomarker results
CSF levels of A␤ , A␤ , T-tau, and P-tau 181 were determined with commercially available single-analyte ELISA kits (INNOTEST ® ␤-AMYLOID(1-42), ␤-AMYLOID(1-40), hTAUAg, and PHOSPHO-TAU(181P); Fujirebio Europe). For each assay run, tests were performed as described earlier [52] . The only difference with the formerly published protocol was that the threshold of acceptance for intra-assay variation (calculated as (max-min) x 100/average) was decreased to 20%. The laboratory technician was blinded for the clinical diagnoses when performing the tests. The concentration ranges of the test kits are described in the package inserts (A␤ : 125-2000 pg/mL, A␤ 1-40 : 7.8-1000 pg/mL, T-tau: 75-1200 pg/mL, P-tau 181 : 15.6-500 pg/mL).
For the interpretation of the CSF biomarker results, in-house validated cutoff values (in autopsyconfirmed AD versus cognitively healthy elderly) [53, 54] were used (A␤ 1-42 <638.50 pg/mL, T-tau >296.50 pg/mL, P-tau 181 >56.50 pg/mL, A␤ 1-42 / A␤ 1-40 <0.067, and A␤ 1-42 /T-tau <2.153). Consistent with the IWG-2 criteria for AD [10] , a CSF biomarker profile was considered to be suggestive for AD if the CSF A␤ value was below the cutoff, in combination with T-tau and/or P-tau 181 values above the threshold. CSF biomarker results were not included in the consensus clinical diagnosis made by the panel.
Imaging biomarkers
Data acquisition
Subjects underwent a 35-min brain MRI scan acquired on a 3T MRI scanner with a 32-channel head coil (Siemens Trio/PrismaFit, Erlangen, Germany). The three-dimension (3D) magnetization-prepared rapid gradient-echo (MP-RAGE) (TR/TE = 2200/2.45 ms) was used to obtain 176 axial slices without slice gap and 1.0 mm nominal isotropic resolution (FOV = 192×256 mm). The acquisition time of the axial T1-weighted MP-RAGE sequence was 5.07 min.
PET image acquisition consisted of a 10-min static (30-min post-injection) [ 18 F]FDG PET scan, and a 60-min dynamic or 10-min static (50-min postinjection) [ 18 F]AV45 PET scan. Both PET scans were acquired on a Siemens Biograph mCT 64 slice TOF PET (Siemens, Erlangen, Germany). All PET images were corrected for random and scattered coincidences and attenuated based on a delayed coincidence window and a low dose computed tomography (CT), respectively. Simultaneously with the dynamic [ 18 F]AV45 PET acquisition, continuous arterial blood sampling was performed by a coincidence detector system (Twilite, Swisstrace, Switzerland) to measure radioactivity in blood. In addition, seven manual blood samples were collected at discrete time points to determine the fraction of unchanged [ 18 F]AV45 (i.e., without metabolites) in plasma. More details on the dynamic [ 18 F]AV45 PET protocol and radiometabolite analysis are described elsewhere [37] .
Image analyses
The clinical panel (SE, SVM, TVDB) visually rated all MRI scans to assess hippocampal atrophy by consensus, based on the Scheltens scale [55] .
[ 18 F]FDG PET images were visually classified (by SC) using a 3-point rating scale (no AD, equivocal, and AD). Scans were classified as visually positive
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for AD using the following criteria: hypometabolism in the temporal and parietal lobes, posterior cingulate gyrus, and precuneus. Following visual assessment, quantitative analysis was done using MIMneuro, an automated and quantitative analysis software application. The algorithm registers each brain to a standard template, allowing for comparisons to a normal database comprising of 43 cognitively healthy controls with an age between 41 and 80 years. Both sets of brains (controls and subjects) are normalized to the mean activity of the whole brain, pons, and cerebellum before comparison. Tracer uptake between a subject and controls is compared on a voxel-by-voxel basis allowing for calculation of zscores (z = [mean subject -mean controls ]/SD controls ).
Inter-frame motion correction of the dynamic [ 18 F]AV45 PET images and PET-MRI co-registration were completed in PMOD v3.6 (PMOD Technologies Ltd., Zurich, Switzerland) [37] . From the dynamic [ 18 F]AV45 PET images, regional V T was extracted using a two-tissue compartment model with metabolite-corrected plasma input function. From the 50-60 min time frame of the static and dynamic [ 18 F]AV45 PET scans, SUVR values were calculated as the volume-weighted average uptake in the frontal, parietal and temporal lobes, with either cerebellar grey matter or whole subcortical white matter as the reference region (SUVR CB and SUVR WM , respectively). All data was corrected for partial volume effects.
For visual investigation, three nuclear medicine physicians (AA, SC, SiS) who were blinded for clinical diagnoses, separately performed a databaseassisted analysis in which the [ 18 F]AV45 PET uptake pattern of all subjects was compared to a normal pattern based on z-score maps (PNEURO v3.6, PMOD Technologies Ltd., Zurich, Switzerland). To this end, voxel-based representations of [ 18 F]AV45 SUVR (reference: cerebellar grey) were created from the 50-60 min time window and all images were spatially normalized to the Rorden clinical template [56] . The brain norm was created from a set of SUVR images acquired with amyloid negative normal controls (n = 9) and normalized to the same space. Each z-score map was classified for A␤ according to the pattern of tracer uptake observed in cortical grey matter areas, and were visually rated as either positive (PET+) or negative (PET-). Scans were considered PET+ if, (1) specific cortical uptake was higher or equal to white matter uptake in two or more brain areas; and (2) there was reduction or loss of the grey-white contrast. In case of discordance between raters, consensus was reached on discrepant reads (n = 13). All image biomarkers, visual and quantitative measures, were not included in the consensus clinical diagnosis made by the panel.
Statistical analyses
Distribution of categorical variables within subject groups were analyzed with a Chi-Square test, and percentages were reported. Cohen's κ coefficient was used to determine the agreement of measures for categorical variables (CSF versus amyloid-PET measures). Demographic comparisons were based on one-way ANOVA tests with post hoc Bonferroni tests, or in case of no normal distribution or low numbers per group (n < 20), Mann Whitney U tests. Area under the curves (AUCs) of receiver operating characteristics (ROC) curves were calculated for continuous variables (V T , SUVR WM , SUVR CB , CSF A␤ )and cutoffs were determined. Linear correlation analyses were performed, and p-and Pearson's R-values were reported. Logistic regression models were fitted with the results of the PET scan as dependent variable (either V T , SUVR CB , or SUVR WM ). The PET scan results were dichotomized according to the calculated cutoffs. Independent variables were either CSF A␤ or A␤ 1-42 /A␤ , or these CSF biomarkers in combination with Ttau and/or P-tau 181 . CSF A␤ or A␤ 1-42 /A␤ were included as dichotomized variable (according to the cutoffs). T-tau and P-tau 181 were entered as continuous variables. Logistic regression models calculated the AUC, using the predicted probabilities from the logistic regression models, and Cohen's κ coefficients.
For all analyses, p-values below 0.05 were considered significant. All statistical analyses were performed using GraphPad Prism 6 and IBM SPSS Statistics 23.
Concordance between A␤ CSF (A␤ 1-42 , A␤ 1-42 /A␤ 1-40 , A␤ 1-42 /T-tau, (A␤ 1-42 /A␤ 1-40 )/Ttau) and [ 18 F]AV45 PET (visual, V T , and SUVR) was defined as the proportion of individuals positive or negative for both biomarkers (i.e., concordant positive CSF+/PET+, or concordant negative CSF-/PET-). Discordance between CSF and [ 18 F]AV45 PET was defined as the proportion of subjects with only one abnormal biomarker (i.e., discordant positive CSF, CSF+/PET-, or discordant negative CSF, CSF-/PET+).
RESULTS
Patient recruitment
The cohort consists of 78 subjects (dementia (n = 17), MCI (n = 48), and cognitively healthy controls (n = 13)), and only baseline results are reported. All subjects underwent the complete neuropsychological test battery, brain imaging scans (including MRI, [ 18 F]FDG PET, and [ 18 F]AV45 PET scans), and in 67 subjects LP was performed. In total, ten subjects refused LP of which most of them were controls (n = 6); the other four subjects were three MCI and one dementia patient. LP failed in one MCI patient. Dynamic [ 18 F]AV45 PET scans (n = 47) were performed in 12 controls, 24 MCI, and 11 AD dementia patients, whereas static [ 18 F]AV45 PET scans (n = 31) were investigated in one control, 24 MCI, and six AD dementia patients. SUVR was calculated in all subjects (n = 78, with CSF available in seven controls, 44 MCI, and 16 AD dementia patients), whereas V T could be calculated in 45/48 subjects (with CSF available in five controls, 22 MCI, and ten AD dementia patients) as three subjects were excluded for V T analysis as their metabolite profile or arterial input function could not be obtained.
Study population (Table 1)
In the studied cohort of 67 subjects that underwent LP, gender and apolipoprotein E (APOE) 4 status (carriers/non-carriers) were not significantly different between groups (p = 0.839 and p = 0.807, respectively), whereas the control subjects were significantly younger at inclusion compared to both the MCI and AD dementia patients. MMSE scores were significantly different between the three groups, with the lowest scores in AD dementia patients and highest scores in the control subjects. No significant differences were detected between the groups for education.
CSF and amyloid-PET analyses
Comparing AD dementia patients and control subjects, all three core AD CSF biomarkers (A␤ 1-42 , T-tau, and P-tau 181 ), and all three ratios (A␤ /A␤ 1-40, A␤ 1-42 /T-tau, and (A␤ 1-42 /A␤ 1-40 )/T-tau) were significantly different as indicated in Table 1 . The only single CSF biomarker that was significantly different between MCI and AD dementia patients was P-tau 181 . No significant difference was found for A␤ . The CSF A␤ 1-42 /T-tau ratio was significantly different between all groups. The CSF (A␤ 1-42 /A␤ 1-40 )/T-tau ratio was significantly different in AD dementia compared to MCI and cognitively healthy control subjects.
Forty-four [ 18 F]AV45 PET scans were consensus rated as suggestive for AD (in controls 31%, MCI 63%, and AD dementia 59%). Comparing MCI patients and cognitively healthy controls, visually rated [ 18 F]AV45 PET scans were significantly different, whereas a trend was found between AD dementia patients and controls (data not shown). There was no significant difference between MCI and AD dementia patients. Quantitative, V T and SUVR CB , were significantly different between MCI or AD dementia patients and cognitively healthy controls as indicated in Table 1 . No significant differences were detected for SUVR WM , whereas this [ 18 F]AV45 PET measure was significantly different in the total population between MCI or AD dementia patients and cognitively healthy controls (Table 1) .
Concordance/discordance between CSF Aβ and amyloid-PET measures
Biochemical analysis of the amyloid markers
The cutoff value for cortical mean [ 18 F]AV45 PET SUVR CB was 1.203 (AUC = 0.778, sensitivity = 100%, and specificity = 66.7%) and cutoff value for cortical mean [ 18 F]AV45 PET SUVR WM was 0.485 (AUC = 0.778, sensitivity = 100%, and specificity = 55.6%), calculated based on the AD dementia and cognitively healthy control subjects. Subjects with SUVR values below the cutoffs were grouped as normal (PET-) and above as abnormal (PET+).
We detected an increased concordance in the visual, SUVR, and V T [ 18 F]AV45 PET values when the CSF A␤ 1-42 /A␤ 1-40 ratio was applied instead of A␤ 1-42 alone (Fig. 1) , with no difference for concordance with both cortical mean SUVR values. The concordance between CSF A␤ 1-42 and amyloid-PET measures was the highest for visually rated PET scans (κ = 0.473), whereas the SUVR measures had the highest concordance when the CSF A␤ 1-42 /A␤ 1-40 ratio was applied (SUVR CB : κ = 0.622 and SUVR WM : κ = 0.641). Logistic regression models, including T-tau or P-tau to CSF A␤ and A␤ 1-42 /A␤ 1-40 showed higher Cohen's κ coefficients for V T and both SUVR measures when the CSF A␤ 1-42 /A␤ 1-40 ratio was applied compared to CSF A␤ 1-42 alone (Table 2 ). In case both CSF tau values were included in the logistic regression models concentration was close to the cutoff of 638.50 pg/mL (726 pg/mL) and both tau markers were abnormal (T-tau: 505 pg/mL and P-tau 181 : 91.5 pg/mL). Applying the A␤ 1-42 /A␤ 1-40 ratio, the CSF amyloid marker changed to abnormal for this subject, and thus in concordance with [ 18 F]AV45 PET (CSF+/PET+).
In the MCI and dementia groups, 18 patients had concordant negative amyloid markers (CSF-/PET-), 17 had at least one positive amyloid marker (CSF-/PET+ or CSF+/PET-), and 25 were positive for both amyloid markers (CSF+/PET+) as shown in Table 4 . With regard to discordant MCI and dementia patients (n = 17), 13 patients were amyloid positive on [ 18 F]AV45 PET but had normal CSF A␤ values (CSF-/PET+). In total, ten patients had A␤ concentrations that were only slightly (within +15%) above the cutoff of 638.50 pg/mL, whereas their T-tau values were suggestive for AD in all cases and Ptau 181 was abnormal in 9/10 patients (Table 5) . When the CSF A␤ 1-42 /A␤ 1-40 ratio was applied seven out of ten subjects became concordant.
In the total population, 23 individuals had a negative concordance (CSF-/PET-) of which 15 suspected non-AD pathology (SNAP) subjects were identified and consisted of three controls, eight MCI, and four AD dementia patients. Eleven subjects had abnormal CSF values for both T-tau and P-tau 181 , Table 4 ). In AD dementia patients, the highest concordance was detected in CSF A␤ 1-42 /A␤ 1-40 and A␤ 1-42 /T-tau for SUVR, with no difference for concordance with the two SUVR measurements. For MCI patients, all three ratios were in higher concordance than A␤ alone; however, A␤ 1-42 /T-tau achieved the highest concordance with SUVR in which SUVR CB outperformed SUVR WM . The (A␤ 1-42 /A␤ 1-40 )/T-tau ratio resulted in more discordant positive CSF controls (CSF+/PET-). In all groups, the highest concordance for V T was found by applying both the CSF A␤ 1-42 /A␤ and A␤ 1-42 /T-tau ratios (Table 4) .
The ratios ensured a change from discordant negative CSF (CSF-/PET+) to concordant positive (CSF+/PET+) in AD dementia and MCI patients (Fig. 3) .
As shown in Fig. 4 , all CSF A␤ concentrations were compared to SUVR WM as this [ 18 F]AV45 PET quantitative measure correlated stronger to CSF values than SUVR CB and V T . A␤ 1-42 /A␤ and A␤ 1-42 /T-tau ratios had an increased concordance compared to CSF A␤ 1-42 alone. By applying (A␤ 1-42 /A␤ 1-40 )/T-tau the concordance increased as well compared to A␤ 1-42 alone, however this ratio is less concordant with PET compared to the two other ratios. In addition, comparable concordance was found when the CSF ratios (B-D) and the new CSF A␤ 1-42 cutoffs (A) were applied. As the CSF A␤ 1-42 /A␤ 1-40 ratio was applied Cohen's κ coefficient was 0.641 (B, horizontal black dotted line) and the new CSF A␤ 1-42 cutoffs showed a Cohen's κ coefficient of 0.647 (A, green dotted line) and 0.853 (A, purple dotted line). Nevertheless, the new SUVRbased A␤ 1-42 /A␤ 1-40 cutoffs were comparable to the autopsy-based A␤ 1-42 /A␤ 1-40 cutoffs and did not increase the concordance further (B).
DISCUSSION
We found an increased concordance between amyloid markers, CSF A␤, and [ 18 F]AV45 PET, when shown in this figure as V T is still the gold standard and SUVR WM is stronger correlated to CSF concentrations compared to SURV CB , in which no significant difference was detected between both SUVR measures. In total, 13% patients had only one abnormal amyloid marker when CSF was compared to SUVR WM , of which 10% had a positive amyloid-PET scan (CSF-/PET+), whereas only 3% of the patients had an abnormal CSF A␤ 1-42 /A␤ 1-40 value (CSF+/PET-). For CSF compared to V T 19% had discordant amyloid markers, of which 9% had a positive amyloid-PET scan (CSF-/PET+), whereas 10% of the patients had an abnormal CSF A␤ the A␤ 1-42 /A␤ 1-40 ratio was applied compared to A␤ alone, which was in line with recent published studies [25, 30, 31] . In literature, if CSF A␤ 1-42 is reported discordant from amyloid-PET, the CSF findings are often positive rather than CSF negative [16, 18, 25, 31] . Our study, however, demonstrated the opposite, namely a smaller proportion of CSF+/PET-and more individuals with CSF-/PET+ when using CSF A␤ . Assuming a correct clinical diagnosis of the AD patients, a higher proportion of CSF A␤ 1-42 positive individuals was expected in our study since CSF A␤ 1-42 changes to abnor- mal at an earlier stage in AD than the amyloid load can be visualized using PET [32] . In literature, similar discrepancies with a higher portion of CSF-/PET+ have been described for CSF A␤ alone [17, 20, 23, 24] . However, none of these studies have questioned the CSF cutoffs used in their studies.
The CSF A␤ cutoff used in the current cohort was established in an autopsy-confirmed AD dementia population (n = 73) as compared to cognitively healthy controls (n = 100) [52] , which reflects two extremes of clinically diagnosed groups. A cutoff only based on pathological individuals at the end of the disease spectrum (AD dementia) detects the most severe biochemical changes and does not take clinical shifts within the disease process into account. We therefore dichotomized all subjects in our entire cohort, including not only AD but also MCI and healthy control cases, into abnormal and normal [ 18 F]AV45 PET values and calculated new A␤ cutoffs based on the two different reference regions (SUVR CB and SUVR WM ) used in the SUVR measurements. This exercise was performed only to show the differences in a CSF A␤ cutoff calculated in clinically diagnosed cognitively healthy controls, MCI, and AD dementia patients as compared to an autopsy-confirmed AD dementia population versus cognitively healthy controls. Using the amyloid-PET instead of neuropathology as the gold standard, we detected an increased cutoff for the A␤ 1-42 values, which confirms a previous study [24] . CSF A␤ cutoffs are often selected to maximize the discriminability between controls and AD dementia patients, and such a method may result in a more conservative and lower CSF A␤ cutoff. Moreover, the use of amyloid-PET positivity as a standard of truth overcomes this problem. As a consequence, the method used to calculate the CSF cutoffs should depend on the context in which the biomarkers should be used (e.g., identifying presymptomatic subjects for clinical trials versus confirming AD dementia). In this study, the increase of the CSF A␤ 1-42 cutoff led to an increased concordance between A␤ CSF and amyloid-PET with a decreased number of CSF-/PET+ and an increased number of positive concordance (CSF+/PET+) as expected. Moreover, the classification changed to an increase of positive concordance instead of discordant negative CSF. This increase in concordance was also achieved by applying A␤ 1-42 /A␤ and A␤ 1-42 /T-tau ratios. Nevertheless, CSF tau markers change later in the pathophysiological process [57] and will likely be outperformed by the A␤ 1-42 /A␤ 1-40 ratio when it comes to early clinical detection of AD. The CSF A␤ 1-42 /A␤ 1-40 ratio also corrects for possible effects of disease specific inter-individual variability in A␤ metabolism (production and/or clearance) [34] [35] [36] . Indeed, patients with CSF A␤ values slightly above the cutoff (within +15% range of the cutoff of 638.50 pg/mL) were in concordance with [ 18 F]AV45 PET when the CSF A␤ 1-42 /A␤ 1-40 ratio was applied. Another explanation for the higher concordance when using the A␤ 1-42 /A␤ 1-40 ratio is variability due to pre-analytical and analytical factors affecting A␤ measured values [58, 59] . A shift in the A␤ 1-42 cutoff will have a larger effect than if the A␤ 1-42 /A␤ 1-40 ratio is applied because the ratio minimizes the effect on the classification in amyloid positive versus negative.
Analyzing the quantitative [ 18 F]AV45 measures, the strongest association was found between CSF A␤ and [ 18 F]AV45 PET SUVR WM compared to SUVR CB . In a subpopulation of this cohort, the gold standard V T correlated better with SUVR WM than with SUVR CB as described by Ottoy et al. [37] . These findings suggest whole subcortical white matter to be a better reference region for SUVR, although to date the most widely used references for quantitation of amyloid-PET are the entire cerebellum and cerebellar grey matter [14] . The cerebellum is commonly chosen since low levels of insoluble fibrillar A␤ have been demonstrated in sporadic AD, which was also confirmed by post-mortem histopathology [15] . In contrast, recent studies showed that subcortical white matter as a reference region resulted in increased power to detect longitudinal cortical SUVR changes and A␤-modifying treatment effects [60] [61] [62] [63] . In addition, cerebellar grey ROIs are highly vulnerable to noise due to their low signal level, and proximity to the edge of the scanner FOV where noise and truncation can occur.
Although this study benefits from a wellcharacterized cohort that was diagnosed according to the strict and standardized application of the most recent diagnostic criteria, a potential limitation of this study is the younger age of the cognitively healthy controls, which were not age-matched to the patients. However, the proportion of preclinical AD individuals will be smaller in younger cognitively healthy controls than when we would have used an age-matched control group. Comparing the clinical diagnoses made by the referring physician and the consensus-based diagnoses we detected discrepancies in three subjects. These three subjects were clinically diagnosed as MCI, whereas the panel concluded that they should have been diagnosed as AD dementia due to the fact that these patients were not completely independent with regard to activities of daily living, including handling money decisions. Another limitation of the study is the low number of cognitively healthy controls. Nevertheless, same findings would have been found in case the cognitively healthy controls were excluded from the biochemical analyses. The CSF samples have not been analyzed simultaneously, and thus inter-assay variability might be an issue, which is a potential limitation of this study.
In summary, in a clinical setting of MCI and dementia due to AD, a higher concordance between amyloid-PET imaging and CSF A␤ can be achieved if the ratio A␤ 1-42 /A␤ 1-40 ratio is applied. This finding is of utmost importance for the biomarker-based diagnosis of AD as well as for the selection of subjects for clinical trials with potential disease-modifying therapies.
